Herbal Medicine Allergy, Mild Cognitive Impairment
Conditions
Brief summary
This study is a 52-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase VI trial being carried out in 20 centers around China. The study population includes amnestic mild cognitive impairment patients (planned a total of 360) aged 55-85 in both gender. Participants will be randomly allocated to Qinggongshoutao bolus (7g per time,2 times per day) and placebo identified to Ginkgo biloba (Ginaton), Ginkgo biloba (Ginaton) (80mg per time, 2 times per day) and placebo identified to Qinggongshoutao bolus, or placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo biloba (Ginaton) for a 52-weeks double-blind treatment period. The primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog) and rate of conversion to dementia. The secondary outcomes are changes from baseline in the Mini-Mental State Examination(MMSE), Delayed Story Recall(DSR), Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24). Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.
Interventions
DRUGQinggongshoutao Bolus
Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
DRUGPlacebos
Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
Sponsors
Dongzhimen Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. cognitive complaints from the patients or their families; 2. objective evidence for memory impairment, delayed story recall test(DSR)\<12.6(age50-64 less than15.5,65-74less than 12.5,older 75 less than10); 3. normal general cognitive function, with Mini-Mental State Examination (MMSE) score of between 24 and 30 (including 30); 4. preservation of activities of daily living, with Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24) score between 38 and 52; 5. cognitive disorders as evidenced by clinical evaluation, with clinical dementia rating scale=0.5,memory domain = 0.5; 6. absence of dementia, not sufficiently impaired cognitively and functionally to meet DSM-IV criteria, 7. enough vision and hearing to accomplishment neuropsychological test; 8. capability to read words and write simple sentence; 9. capability and willingness to give informed consent and to comply with the study procedures.
Exclusion criteria
1. non amnestic Mild cognitive impairment; 2. meeting the diagnostic criteria for dementia; 3. cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, epilepsy vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor ,or drug abuse or alcohol abuse 4. having significant psychiatric disease, depression, the Hamilton depression scale \>12; CT or MRI scan showed central nervous system infections Infarction or focal lesions within 12 months，the Hachinski Ischemic Scale (HIS)\>4; 5. combined following disease: diabetes; poor controlled hypertension or severe arrhythmias; or suffered from heart infarction within 3 months; severe asthma or COPD; severe indigestion; gastrointestinal tract obstruction; gastroduodenal ulcer; 6. used cholinesterase inhibitors or memantine within 1 month; 7. history of hypersensitivity to the treatment drugs; 8. concomitant drugs with the potential to interfere with cognition; 9. administration of other investigational drugs; severe impairment of the functions of the kidney or liver; 10. vegetarians or contraindications for animal innards.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to end of double-blind treatment of Alzheimer Disease Assessment Scale-cognitive subscale | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |
| Change from baseline to end of double-blind treatment of rate of conversion to dementia | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |
Secondary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination(MMSE) | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |
| Change from baseline to end of double-blind treatment of Delayed Story Recall test (DSR) | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |
| Change from baseline to end of double-blind treatment of Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24) | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |
Countries
China
Outcome results
None listed